Heyholder
‹ Activism Filings

CJ Bioscience Periodic Report

CJ Bioscience

AI summary · Not investment advice

CJ Bioscience sold KRW 0.9 billion in Q3 and lost KRW 4.9 billion from its main business, a smaller loss than KRW 6.1 billion a year earlier.

Operating profit · 3 months

KRW -4.9 billion

Key facts

Revenue (3 months)
KRW 862.7 million
Net income (3 months)
KRW -4.8 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 737.9 million
Revenue (year to date)
KRW 2.5 billion
Operating profit (prior-year 3 months)
KRW -6.1 billion
Operating profit (year to date)
KRW -16.7 billion
Net income (prior-year 3 months)
KRW -5.8 billion
Net income (year to date)
KRW -16.1 billion

Commentary

AI commentary · Not investment advice

What happened

CJ Bioscience filed its quarterly report on a consolidated basis for the third quarter of 2026. Sales for the latest 3 months were KRW 862.7 million. That is 16.9% higher than the same 3 months a year earlier, and 4.0% lower than the previous quarter. Cumulative sales this year are KRW 2.54 billion.

In the company's terms

Operating profit (money earned from the core business) for the latest 3 months was a loss of KRW 4.93 billion. A year earlier, the same period showed a loss of KRW 6.08 billion. The cumulative operating loss this year is KRW 16.67 billion.

What changes for shareholders

Net income (the final profit after taxes and all other items) for the latest 3 months was a loss of KRW 4.77 billion. A year earlier, it was a loss of KRW 5.83 billion. The cumulative net loss this year is KRW 16.10 billion.

Comments

No comments yet

Comments from shareholders will appear here.